PWMG
STOK icon

Prestige Wealth Management Group’s Stoke Therapeutics STOK Stock Holding History

Prestige Wealth Management Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.51K Hold
200
– – ﹤0.01% 502
2025
Q4 		$6.35K Buy
+200
New +$6.01K ﹤0.01% 526

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Prestige Wealth Management Group's STOK Position: Q1 2026 in Review

Prestige Wealth Management Group held its Stoke Therapeutics (STOK) position steady in Q1 2026 at 200 shares worth $6.51K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

Prestige Wealth Management Group first reported a position in STOK in Q4 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Prestige Wealth Management Group held 200 shares of Stoke Therapeutics worth $6.51K as of Q1 2026.
  • Prestige Wealth Management Group left its Stoke Therapeutics share count unchanged in Q1 2026.
  • Stoke Therapeutics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q1 2026, its #502 holding.
  • Prestige Wealth Management Group first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Prestige Wealth Management Group's 13F filing for Q1 2026, filed 13 May 2026.